T cell receptor and antigen-presenting cell surface antigens (TCR-APC complex)

The interaction between T cell receptors (TCR) and antigen-presenting cell (APC) surface antigens is the fundamental mechanism of the adaptive immune system. The TCR recognizes processed antigenic peptides presented by Major Histocompatibility Complex (MHC) molecules on the surface of APCs, such as dendritic cells, macrophages, and B cells. This primary recognition event, often supported by co-receptors like CD4 or CD8 and co-stimulatory molecules like CD28/B7, triggers a signaling cascade that leads to T cell proliferation, cytokine production, and effector function. In disease states, this system can be dysregulated, leading to either insufficient immune responses against tumors and pathogens or overactive responses in autoimmunity and transplant rejection. Therapeutic interventions include monoclonal antibodies that block inhibitory checkpoints, fusion proteins that interfere with co-stimulation, and engineered TCR therapies designed to redirect T cells toward specific cancer antigens.

Other names

T-cell receptor complexMHC-peptide complexTCR-pMHC interactionAntigen-presenting cell surface markersMajor histocompatibility complex

Drugs targeting this system typically act by blocking co-stimulatory signals, inhibiting TCR signaling through CD3 binding, or preventing the interaction between inhibitory receptors (checkpoints) and their ligands on APCs to enhance or suppress T cell activation.